Prelude Therapeutics, Inc. (PRLD)
2.875
+0.10
(+3.42%)
USD |
NASDAQ |
Feb 23, 10:22
Prelude Therapeutics SG&A Expense (Quarterly) : 5.21M for Sept. 30, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| BioLife Solutions, Inc. | 14.60M |
| Immunome, Inc. | 10.94M |
| Incyte Corp. | 390.41M |
| Aclaris Therapeutics, Inc. | 4.871M |
| Relay Therapeutics, Inc. | 12.13M |